01 Increasing Accessibility of Oral Contraceptives Through Nonprescription Channels The contraceptive drugs market is shifting toward broader consumer access, particularly for oral contraceptives that can be obtained without a prescription. Regulatory changes are reducing the need for routine clinical visits for selected products, improving convenience and potentially expanding access among consumers who face barriers related to healthcare availability, cost, or time. This trend is increasing the importance of consumer-friendly labeling, self-selection, and pharmacy and retail distribution. In July 2023, the U.S. FDA approved Opill (norgestrel) as the first daily oral contraceptive in the United States available without a prescription, allowing consumers to purchase it through retail stores and online channels.
02 Greater Emphasis on Personalized and Evidence-Based Contraceptive Selection The contraceptive drugs market is increasingly emphasizing individualized method selection based on medical conditions, physiological characteristics, preferences, and reproductive goals. Updated clinical guidance is supporting healthcare providers in selecting appropriate hormonal and non-hormonal methods while addressing safety, effectiveness, and method-specific considerations. This is encouraging manufacturers and healthcare systems to support a broader range of contraceptive options rather than relying on a single dominant formulation. In November 2025, WHO released the sixth edition of its Medical Eligibility Criteria for Contraceptive Use, incorporating 112 new or updated recommendations across 25 family-planning methods to support safer, more individualized contraceptive care.
01 Unmet Family-Planning Needs Sustain Demand for Contraceptive Drugs The continuing need to prevent unintended pregnancies provides a fundamental source of demand for contraceptive drugs. Although modern contraceptive use has expanded globally, substantial unmet need remains, particularly where access to healthcare services and specific contraceptive methods is limited. In July 2025, WHO reported that 1.1 billion women of reproductive age worldwide had a need for family planning in 2021, including 164 million with an unmet need for contraception.
01 Concerns About Side Effects and Method Suitability Can Limit Contraceptive Drug Use Contraceptive drug adoption can be constrained when users discontinue or avoid hormonal methods because of concerns about side effects, bleeding changes, contraindications, or uncertainty about which formulation is appropriate.
01 Expansion of Over-the-Counter Contraception Creates New Consumer Access Opportunities Regulatory approval of selected contraceptives for over-the-counter sale is expanding market access, allowing pharmaceutical manufacturers to serve customers through pharmacies, retail outlets, and e-commerce platforms. Manufacturers with products supported by strong safety profiles and clear consumer instructions are positioned to benefit from this access model.
01 Adherence and Correct Use Remain Critical to Contraceptive Drug Effectiveness oral contraceptives can become less effective when doses are missed or taken incorrectly, while emergency contraceptive effectiveness depends on timely administration. Manufacturers and healthcare providers therefore face the challenge of improving adherence, consumer understanding, and access to clear usage information.
March 2026 Bayer expanded its women’s healthcare portfolio with continued development and global access initiatives for hormonal contraceptive therapies, strengthening its position in reproductive health solutions.
September 2025 Organon expanded its contraception portfolio through new market access initiatives and product availability programs, supporting broader access to family planning solutions.
May 2025 Viatris expanded its women’s health product portfolio with new reproductive healthcare solutions, including contraceptive offerings, to improve access across global markets.